Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Survodutide cycle length: what human studies ran

InvestigationalAHuman trial evidence
Short answer: there is no established Survodutide cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Phase 2 obesity: 46 weeks (20-week escalation, 26-week maintenance) 5. Phase 2 MASH: 48 weeks (24-week escalation, 24-week maintenance) 4. Phase 1 cirrhosis multiple-dose cohorts: 28 weeks 8. Japanese phase 1: 16 weeks 7.
  2. SYNCHRONIZE-1 and SYNCHRONIZE-2: primary assessment at week 76 1,2; SYNCHRONIZE-MASLD: 48 weeks 3; SYNCHRONIZE-JP: 76 weeks 14; SYNCHRONIZE-CN: 76 weeks with primary endpoints at week 52 15.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Survodutide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Survodutide cycle length?
No. Human studies administered Survodutide for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Survodutide?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Survodutide dosing reference Full research page

References

  1. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1) N Engl J Med. 2026
  2. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (SYNCHRONIZE-2) N Engl J Med. 2026
  3. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Nat Med. 2026
  4. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis N Engl J Med. 2024
  5. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol. 2024
  6. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy Mol Metab. 2022
  7. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906 in healthy Japanese men with overweight/obesity Diabetes Obes Metab. 2023
  8. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/GLP-1 receptor dual agonist, in cirrhosis J Hepatol. 2024
  9. SYNCHRONIZE-1 registration record (NCT06066515) ClinicalTrials.gov. 2023
  10. SYNCHRONIZE-2 registration record (NCT06066528) ClinicalTrials.gov. 2023
  11. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  12. Drugs@FDA application data queried through openFDA for survodutide (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  13. PubChem compound records for survodutide PubChem. 2026
  14. Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial Diabetes Obes Metab. 2026
  15. Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE-CN) Diabetes Ther. 2026
  16. A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE-CVOT, NCT06077864) ClinicalTrials.gov. 2026
  17. A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight (registry results: participant flow group descriptions) ClinicalTrials.gov. 2023
  18. A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes (registry results: participant flow group descriptions) ClinicalTrials.gov. 2022
  19. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Diabetologia. 2024